# antibodies -online.com







## anti-PD-L1 antibody (Extracellular Domain)

**Images** 



**Publications** 



_					
U	١V	e	rv	le	V

Quantity:	0.1 mg	
Target:	PD-L1	
Binding Specificity:	Extracellular Domain	
Reactivity:	Human	
Host:	Mouse	
Clonality:	Monoclonal	
Conjugate:	This PD-L1 antibody is un-conjugated	
Application:	Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))	

#### **Product Details**

Immunogen:	Recombinant human PD-L1 extracellular domain		
Clone:	27A2		
Isotype:	lgG2b		
Specificity:	This antibody reacts with human CD274 antigen.		
Purification:	Protein A agarose		

### Target Details

Target:	PD-L1	
Alternative Name:	CD274 / PDL1 (PD-L1 Products)	
Background:	Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was	

identified by searching for mo lecules that share homology with the immunogloblin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-lg were activated, proliferation and production of IFN-  $\gamma$  GM-CSF and IL-10 from the T cells were enhanced. The role of PD-L1 is now debatable. Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Gene ID: 29126

NCBI Accession: NP\_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints

For Research Use only

#### **Application Details**

Application Notes: Optimal working dilution should be determined by the investigator.

#### Handling

Restrictions:

Concentration: 1.0 mg/mL

Buffer: PBS containing 50 % glycerol, pH 7.2. No preservative is contained.

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Upon receipt, store (in aligouts) at -20 °C.

#### **Publications**

Product cited in:

Gadiot, Hooijkaas, Kaiser, van Tinteren, van Boven, Blank: "Overall survival and PD-L1 expression in metastasized malignant melanoma." in: **Cancer**, Vol. 117, Issue 10, pp. 2192-201, (2011) (PubMed).

Hino, Kabashima, Kato, Yagi, Nakamura, Honjo, Okazaki, Tokura: "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma." in: **Cancer**, Vol. 116, Issue 7, pp. 1757-66, (2010) (PubMed).


Schuchmann, Meyer, Distler, von Stebut, Kuball, Schnürer, Wölfel, Theobald, Konur, Gregor, Schreiner, Huber, Galle, Otto, Herr: "The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation." in: **American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons**, Vol. 8, Issue 11, pp. 2434-44, (2008) (PubMed).

Fancke, Suter, Hochrein, OKeeffe: "M-CSF: a novel plasmacytoid and conventional dendritic cell poietin." in: **Blood**, Vol. 111, Issue 1, pp. 150-9, (2008) (PubMed).

Hamanishi, Mandai, Iwasaki, Okazaki, Tanaka, Yamaguchi, Higuchi, Yagi, Takakura, Minato, Honjo, Fujii: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer." in: **Proceedings of the National Academy of Sciences of the United States of America**, Vol. 104, Issue 9, pp. 3360-5, (2007) (PubMed).

There are more publications referencing this product on: Product page


#### **Images**




#### **Flow Cytometry**

Image 1.

activation; using Microwave



activation; using Autoclave



#### **Immunohistochemistry**

Image 2.